MedTrace Logo

Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

NCT07030348 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 263

Last updated 2025-06-22

No results posted yet for this study

Summary

Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable.

Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, biomarkers related to this are not well understood. This study aims to identify biomarkers for the early diagnosis of pancreatic cancer through duodenal pancreatic juice, which can be easily obtained through an endoscopy.

Conditions

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • University of Colorado, Denver

    collaborator OTHER

  • Do Hyun Park

    lead OTHER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-02
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07030348 on ClinicalTrials.gov